Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jaguar Health, Inc. (NASDAQ: JAGX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors structured access to its capital markets activity and material agreements. Jaguar is a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals, and its filings provide insight into how it finances and supports these programs.
Recent Form 8-K filings describe a range of transactions, including secured and unsecured promissory notes, royalty interest agreements and amendments, PIPE financings involving Series N Perpetual Preferred Stock and common stock with pre-funded warrants, and privately negotiated exchanges of preferred stock for common shares and pre-funded warrants. Other 8-Ks outline at-the-market offering amendments, conditional approval-related developments for Canalevia-CA1, and note purchase agreements backed by deposit account control arrangements and subsidiary guarantees.
Jaguar’s proxy materials, such as definitive proxy statements on Schedule 14A, detail stockholder proposals to approve share issuances under Nasdaq Listing Rule 5635(d), including common stock issuable upon exchange of Series L, Series M, and Series N preferred stock and upon conversion of certain convertible promissory notes and related warrants. These documents also explain voting rights, voting caps for preferred series, and the structure of special and annual meetings.
On this page, users can review Jaguar’s 10-K and 10-Q reports (when available) for broader business and risk disclosures, while Form 4 and related ownership filings provide visibility into insider equity transactions. Stock Titan enhances these filings with AI-powered summaries that highlight key terms in complex documents, such as interest rates, maturity dates, collateral arrangements, voting provisions, and share issuance conditions. Real-time updates from EDGAR ensure that new Jaguar Health filings, including 8-Ks announcing material events, are quickly accessible with plain-language explanations.
Jaguar Health reported 2025 results showing slightly lower sales but much higher losses, while also securing new licensing cash. Net product revenue for the year was $11.5 million, down about 1.5% from 2024. Loss from operations widened to $45.9 million from $30.8 million, and net loss attributable to common stockholders grew to $53.6 million from $38.5 million. Non-GAAP EBITDA was a loss of $48.2 million, larger than the $36.0 million non-GAAP EBITDA loss in 2024. The company noted net revenue rose 5% in the fourth quarter versus the third quarter of 2025.
In January 2026, Jaguar received an upfront payment of $16 million in non-dilutive capital under a U.S. license agreement with Future Pak for its crofelemer drugs Mytesi and Canalevia-CA1, with an additional $2 million payable upon post-closing conditions and $3.0 million already received of up to $20 million in potential milestone and other future payments. The company plans to appeal Nasdaq’s March 5, 2026 noncompliance determination related to Nasdaq Listing Rule 5550(a)(2) at a hearing on April 7, 2026, and delisting is stayed pending the panel’s final decision.
Jaguar Health, Inc. details a diversified gastrointestinal drug business built around crofelemer and related plant-derived therapies. The company licensed U.S. rights to Mytesi and Canalevia-CA1 to Future Pak in January 2026, receiving $16 million in non‑dilutive capital plus a further $2 million tied to post‑closing conditions and eligibility for up to $20 million in milestones. An additional $3.0 million payment followed termination of a buy‑back provision, while Jaguar retains manufacturing responsibilities.
The filing highlights advanced development of a highly concentrated crofelemer powder for oral solution targeting ultra‑rare intestinal failure indications, including microvillus inclusion disease and short bowel syndrome with intestinal failure, supported by multiple orphan drug designations in the U.S. and EU and early proof‑of‑concept data showing parenteral support reductions of up to 37%. Jaguar also pursues NP‑300 for infectious diarrhea with potential access to a tropical disease priority review voucher, markets Gelclair for oral mucositis under a U.S. in‑license, and develops plant‑based mental health drugs through the Magdalena joint venture.
Jaguar Health, Inc. notified the SEC that it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 due to delays compiling material subsequent-event information. The company states it will file the Form 10-K no later than the fifteenth calendar day following the prescribed due date.
Jaguar Health has called a special stockholder meeting to reshape its capital structure. Stockholders will vote on raising authorized voting common shares from 298,000,000 to 500,000,000, increasing total authorized shares to 554,475,074. As of March 2, 2026, 12,419,277 common shares were outstanding.
The board is also seeking authority for two separate reverse stock splits, each at a ratio between 1‑for‑15 and 1‑for‑150, which together could reach an aggregate ratio of up to 1‑for‑22,500 if both are implemented. The board would choose exact ratios and timing within one year of approval for each split.
Another key proposal asks approval, under Nasdaq Listing Rule 5635(d), for issuing common shares upon exchange of a secured promissory note originally totaling $10,810,000 held by Streeterville Capital, LLC. Full exchange of the outstanding balance as of March 12, 2026 could exceed the current share count, meaning substantial potential dilution for existing holders. The board also seeks authority to adjourn the meeting if more time is needed to secure votes.
Jaguar Health, Inc. is asking shareholders to approve multiple capital-structure actions at a Special Meeting on April 20, 2026
The proposals seek (i) to increase authorized voting Common Stock from 298,000,000 to 500,000,000 (total authorized shares from 352,475,074 to 554,475,074); (ii) and (iii) to authorize two discretionary reverse stock splits, each at a ratio between 1-for-15 and 1-for-150; and (iv) to approve, for Nasdaq Rule 5635(d) purposes, the issuance of shares on exchange of a secured promissory note issued to Streeterville Capital with original principal $10,810,000 (outstanding approximately $7,057,500 as of March 12, 2026), which could result in issuance of ~13,232,241 Exchange Shares (about 106.55% of the 12,419,277 shares outstanding as of the Record Date).
The company disclosed Nasdaq non-compliance for a sub-$1 bid price and has appealed; approvals are requested under both the Votes Cast Standard and the Majority of Outstanding Standard to preserve board flexibility. Shareholder votes will also permit adjournments to solicit additional proxies.
Jaguar Health director John Micek received equity awards as board compensation. On December 11, 2025 he was granted stock options for 7,377 shares of common stock at an exercise price of $1.44 per share, expiring on December 11, 2035, under the 2014 Stock Incentive Plan. The options vest monthly over 12 months while he continues serving on the boards of Jaguar Health and its subsidiary Napo Therapeutics.
On the same date he also received 7,377 restricted stock units, each representing one share of common stock, which vest on December 11, 2026. After the grant he directly holds 7,430 common shares, and the vested RSU shares will be delivered on the vesting date specified in the grant notice.
Jaguar Health, Inc. reworked several financing arrangements with Uptown Capital and Streeterville Capital. The company postponed monthly royalty payments under two $12 million royalty interests from April 1, 2026 to July 1, 2026 and reduced each related Royalty Repayment Amount by ten percent, to $11,125,282.54 and $12,428,782.20. Jaguar and subsidiary Napo Pharmaceuticals also amended secured notes with Streeterville: the 2021 Note’s maturity was extended to July 1, 2026 and its Outstanding Balance cut ten percent to $6,596,304.11, while the 2025 Note’s maturity was extended to March 12, 2029 with an Outstanding Balance of $7,048,021.86. Napo granted Streeterville a security interest in specified Lechlemer and TDPRV collateral to secure the 2025 Note. In a separate warrant termination agreement, investors agreed to terminate warrants exercisable for 48,211 shares of Jaguar’s common stock.
Jaguar Health, Inc. reported that Nasdaq notified the company on March 5, 2026 that it is no longer in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price of its common stock has closed below $1.00 per share for the previous 30 consecutive business days.
Nasdaq also stated the company is not eligible for a standard compliance period because it effected one or more reverse stock splits over the prior two years with a cumulative ratio of at least 250-to-1. Unless Jaguar Health requests an appeal before a Nasdaq Hearings Panel by March 12, 2026, its securities would be scheduled for delisting.
Jaguar Health intends to timely request this appeal, which would automatically stay any further suspension or delisting action at least until the hearing process is concluded. The company cautions there can be no assurance that the Panel will grant continued listing or that it will regain and maintain compliance with Nasdaq’s standards.
Jaguar Health, Inc. detailed the terms of a special one-time dividend of its new Series O Convertible Preferred Stock, giving one-tenth of a Series O share for each common share and for common shares issuable under Eligible Warrants outstanding as of the March 2, 2026 record date. The company designated 1,557,000 shares of preferred stock as Series O, which carry no regular dividends and almost no voting rights. Each Series O share has a stated value of $8.01 and will convert into common stock based on a market-based conversion price, subject to a 19.99% beneficial ownership cap per holder. Jaguar may choose to convert all outstanding Series O before December 31, 2026, or they will automatically convert on that date, with any excess above the cap potentially delivered as pre-funded warrants exercisable at $0.001 per share.
Jaguar Health declared a special one-time stock dividend of Series O Convertible Preferred Stock, granting one-tenth of one Series O share for each share of common stock and for Eligible Warrants covering 2,400,765 common shares held on the March 2, 2026 record date. The dividend is expected to be paid on March 4, 2026. The Series O Preferred Stock is non-transferable, pays no dividends, has minimal liquidation preference, and carries almost no voting rights, but will convert into common stock at the company’s election or automatically on December 31, 2026 based on a market-linked conversion price, subject to a 19.99% beneficial ownership cap per holder. Jaguar’s risk disclosures highlight that full conversion of the Series O Preferred Stock and potential future exchanges of approximately $30 million of debt into common stock could result in substantial dilution and pressure on the share price. The company also warns of ongoing risks to maintaining its Nasdaq listing following multiple reverse stock splits and evolving listing standards.